OxSonics Therapeutics Ltd.

https://www.oxsonics.com

OxSonics is a clinical-stage therapeutics company, transforming cancer treatment by harnessing its first-in-class, proprietary technology platform SonoTran® to enhance the delivery and improve the efficacy of oncology drugs. Current oncology drugs are restricted by their poor ability to penetrate solid tumors. SonoTran® is being developed to provide a step-change in the therapeutic index of the drugs without the development costs or delays associated with drug reformulation. It combines Particles that are co-administered independently with an anti-cancer drug, and activated by a novel ultrasound device, creating a localised pumping effect that increases the delivery and penetration of the anti-cancer drug throughout the tumor. SonoTran® is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumor cancers. The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing vizualisation on-screen and in real time. SonoTran® is currently being evaluated in a phase I/IIa proof of concept clinical study in patients with metastatic colorectal cancer with liver metastases. The SonoTran® drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics is based in Oxford in the UK. *

	Start	2019-05-03 existent
	Predecessor	University of Oxford
	Industry	drug delivery technology (drug formulation technology)
	Person	Marzinski, Jérôme (OxSonics 202211– CEO before Cimon Medical + Visiometrics + ev3 + Vexim)
	Person 2	Jeynes-Ellis, Allison (Avillion 201402– CEO before Co-founder + CMO before Wyeth UK + BMS + Novartis)

	Region	United Kingdom (town unspecified)
	Country	United Kingdom (GB)
	Street	Robert Robinson Avenue Oxford Science Park, The Magdalen Centre
	City	OX4 4GA Oxford, Oxfordshire
	Tel	+44-1865-784777
		Address record changed: 2022-11-08

Basic data	Employees	n. a.

		* Document for »About Section«: OxSonics Therapeutics Ltd.. (11/7/22). "Press Release: Jérôme Marzinski Appointed as Chief Executive Officer". Oxford.

		Record changed: 2023-07-10

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for OxSonics Therapeutics Ltd.

[1] OxSonics Therapeutics Ltd.. (11/7/22). "Press Release: Jérôme Marzinski Appointed as Chief Executive Officer". Oxford....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)